Business
Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease
Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease ...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen1{\nBORDER-TOP:0pt; BORDER-RIGHT:0pt; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt; BORDER-LEFT:0pt\n}\n.prngen6{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen5{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prngen4{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:black 0pt; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prntar{\nTEXT-ALIGN: RIGHT\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnvat{\nVERTICAL-ALIGN: TOP\n}\n.prnsbtb0{\nBORDER-TOP:black 0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n LAVAL, QC, Oct. 29, 2020\n \n \n \n \n \n LAVAL, QC\n \n ,\n \n Oct. 29, 2020\n \n /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) (\"Bausch Health\") and its gastroenterology business, Salix Pharmaceuticals (\"Salix\"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to rifaximin for the treatment of sickle cell disease. The FDA's Orphan Drug Designation program provides orphan status to medicines that are intended for the treatment of a rare disease or condition and incentives for companies to study and further develop medicines to bring forward novel treatments.\n \n \n Approximately 100,000 Americans have sickle cell disease, which is a group of inherited red blood cell disorders that affects hemoglobin, the protein...